| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2016: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2013: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Outline of Final Research Achievements |
Here, we show that GRWD1 is a novel oncogene that negatively regulates p53 via the RPL11-MDM2 and RPL23-MDM2 pathways. Furthermore, analyses of several cancer databases reveal that high expression of GRWD1 is associated with poor prognosis of patients suffering from certain cancers. It will become a useful diagnostic method for certain cancers to test the expression levels of GRWD1 in clinical samples. If novel compounds that can interfere with the interaction between GRWD1 and RPL11 (or RPL23) will be identified, they will be powerful novel anti-neoplastic agents.
|
